Expanded Access

Precision BioSciences is currently investigating multiple off-the-shelf allogeneic CAR T cell therapy candidates as potential treatment options for patients with hematologic blood cancers. Precision does not currently offer patients Expanded Access to investigational therapies outside of clinical trials. We believe that facilitating patient participation in our ongoing clinical trials is the best way to speed investigation and subsequent approval of candidate therapies for broad access by providing a rigorous assessment of the products’ benefits, risks, and appropriate uses for patients.

Eligibility requirements and more information about our clinical trials is available at clinicaltrials.gov.